The primary goal of the Translational Microenvironment/Viral Oncology (TMV) Center is to advance the translational application of scientific findings into patient care. TMV Center scientists will be challenged with utilizing our increasing knowledge of immune, inflammatory and patient-specific factors that regulate cancer development, progression, and response to treatment, in order to directly enhance and accelerate patient interventions. Emphasis will be placed on establishing productive scientific collaborations between bench researchers and clinicians, so that fundamental laboratory observations can be rapidly developed into novel therapeutic targets and better prognosticators, tested in preclinical models, and brought to trials in the clinic.
TMV Center research areas of focus include:
- Cancer cell-stromal/inflammatory cell interactions
- Host response and biomarkers of progression in patients with virus-associated malignancy
- Inflammatory, viral and stromal-specific therapeutic strategies
A prototypical example of a clinical question of the TMV Center is why a small subset of individuals develops a particular virus-associated malignancy, when an entire population has been infected with the virus. Utilizing molecular findings from laboratory research in this specific subset of cancer cells, TMV Center investigators will collaborate to develop targeted, virus-specific therapeutic interventions and methods for immunoprevention.
The TMV Center is intended to be highly interactive, both internally as well as with other UPCI Research Programs, and will actively recruit new faculty members to promote integrative and transdisciplinary research. It is anticipated that the TMV Center will play a pivotal role in identifying novel microenvironmental targets for therapeutic intervention that will be tested in combination with more conventional treatments in patients with a variety of cancers.
Interested UPCI researchers can download an application (PDF) for a translational collaborative grant proposal.